Status:
UNKNOWN
Inherited Cancer Early Diagnosis (ICED) Study
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Li Fraumeni Syndrome
Lynch Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
ICED is a prospective sample collection research study, aiming to develop or validate a blood/urine biomarker which could potentially detect cancers early in individuals at high risk of developing can...
Detailed Description
Heritable genetic alterations play a major role in up to 10% of all cancers. There are more than 50 hereditary cancer syndromes identified which predispose an individual to developing certain tumours,...
Eligibility Criteria
Inclusion
- Patients over the age of 18 years old, with no active cancer
- Carriers of a pathogenic/likely pathogenic variant in any of the following genes: TP53, Mismatch Repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM), PTEN, STK11 (Peutz-Jeghers syndrome), CDH1, APC, SMAD4, MUTYH\* (\*biallelic carriers).
- Able to consent to the study.
Exclusion
- Carriers of a variant associated with reduced penetrance (in the view of a geneticist) or a variant of uncertain significance.
- Patients with a malignancy diagnosed in the previous 5 years \[except non-melanomatous skin cancer or cervical carcinoma in situ (CIS)\].
Key Trial Info
Start Date :
July 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 26 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06163365
Start Date
July 26 2022
End Date
July 26 2025
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden NHS Foundation Trust
London, United Kingdom